Histone deacetylases (HDACs) are promising targets for cancer therapy, although their individual actions remain incompletely understood. Here, we identify a role for HDAC2 in the regulation of MDM2 acetylation at previously uncharacterized lysines. Upon inactivation of HDAC2, this acetylation creates a structural signal in the lysine-rich domain of MDM2 to prevent the recognition and degradation of its downstream substrate, MCL-1 ubiquitin ligase E3 (MULE). This mechanism further reveals a therapeutic connection between the MULE ubiquitin ligase function and tumor suppression. Specifically, we show that HDAC inhibitor treatment promotes the accumulation of MULE, which diminishes the t(X; 18) translocation-associated synovial sarcomagenesis by directly targeting the fusion product SS18-SSX for degradation. These results uncover a new HDAC2-dependent pathway that integrates reversible acetylation signaling to the anticancer ubiquitin response.
HIGHLIGHTS MULE undergoes MDM2/ HDAC2-mediated degradation in synovial sarcoma HDAC inhibition promotes MULE stabilization by acetylation and dissociation of MDM2 SS18-SSX fusion oncoprotein is a target of MULE E3 ligase HDAC inhibitors downregulate SS18-SSX stability through the ubiquitin system INTRODUCTION Synovial sarcoma is an incurable malignant soft tissue tumor, which primarily affects children and young adults. Like many other sarcomas, this disease is histologically composed of mesenchymal cells. However, synovial sarcoma displays variable degrees of epithelial differentiation and contains a unique chromosomal translocation t(X; 18), which most commonly fuses the SS18 gene with SSX1 or SSX2 (Nielsen et al., 2015) . Depletion of SS18-SSX by small interfering RNAs (siRNAs) causes apoptotic cell death of human synovial sarcoma cells (Peng et al., 2008; Cai et al., 2011; Carmody Soni et al., 2014) . Conversely, overexpression of SS18-SSX in noncancerous rat fibroblast cells shows transforming activity in a xenograft model (Nagai et al., 2001) . Notably, mice conditionally expressing the SS18-SSX fusion gene in certain cell lineages develop tumors that are pathologically indistinguishable from and molecularly consistent with synovial sarcoma in humans (Haldar et al., 2007) , thus confirming the critical role for SS18-SSX in the pathogenesis of synovial sarcoma.
Fundamental progress has been made in understanding how the SS18-SSX fusion protein promotes tumorigenesis, which indeed involves multiple parallel mechanisms, such as epigenetic remodeling (Su et al., 2012; Kadoch and Crabtree, 2013; Banito et al., 2018; McBride et al., 2018) , cellular adhesion (Eid et al., 2000) , mesenchymal-toepithelial transition (Saito et al., 2006; Barrott et al., 2015) , protein translocation (Pretto et al., 2006) , and microRNA regulation (Hisaoka et al., 2011; Minami et al., 2014) . Such complexities in SS18-SSX action make the development of targeted therapies for synovial sarcoma extremely challenging. Despite the lack of effective treatment options, several lines of evidence have shown that human synovial sarcoma cells are highly sensitive to histone deacetylase (HDAC) inhibitors in cell cultures and in a cell-line-based xenograft model (Ito et al., 2005; Laporte et al., 2017a) . One well-supported explanation for the action of HDAC inhibitors is histone acetylation through which key tumor suppressor genes become epigenetically reactivated (Lubieniecka et al., 2008; Su et al., 2010 Su et al., , 2012 Laporte et al., 2017b) . In the present study, we propose an additional, transcription-independent mechanism whereby HDAC inhibition facilitates proteasomal degradation of the SS18-SSX fusion protein. This action relies mostly on a novel combination of HDAC2 and MDM2 activities in concert with the MULE E3 ligase function. Our findings connect HDAC2 activity to oncogenic protein stabilization via a series of post-translational events, which constitute an acetylation-dependent ubiquitin pathway that may serve as a common therapeutic target in human cancers.
RESULTS

HDAC Inhibitor Treatment Reduces SS18-SSX Levels through the Ubiquitin System
To assess the in vivo efficacy of HDAC inhibition in synovial sarcoma, we generated transgenic mice expressing human SS18-SSX2 fusion oncogene within the myogenic factor 5 (Myf5) lineage (Haldar et al., 2007) . Treatment with the HDAC inhibitor FK228 on a weekly basis significantly reduced growth of mouse synovial sarcomas (Figures S1A and S1B), associated with remarkable cytoreductive activity ( Figures S1C-S1H ). In addition to the histological observations, we noticed that SS18-SSX2 protein abundance was substantially decreased in FK228-treated tumors ( Figures 1A and 1B) . Considering the fusion oncogene dependency in synovial sarcoma, we decided to examine the molecular mechanism of SS18-SSX downregulation upon HDAC inhibition. To this end, we first developed a CRISPR/ Cas9-based genome editing approach for FLAG epitope tagging of endogenous SS18-SSX2 fusion oncoprotein in patient-derived SYO-1 cells (Figures S1I-S1K). Anti-FLAG western blots revealed that SS18-SSX levels remained constant through the early time points of FK228 treatment, but fell drastically after overnight stimulation ( Figure S1L ). Similar results were obtained in cells treated with other structurally different HDAC inhibitors, such as SB939 and PCI-24781 ( Figure 1C ). We also tested this in SS18-SSX1associated synovial sarcoma cells (Yamato-SS) and found that treatment with the HDAC inhibitors FK228 and SB939 led to a marked reduction of SS18-SSX protein levels, coupled with impaired tumor cell growth (Figures 1D and 1E) . Importantly, the mRNA levels of SS18-SSX remained unchanged (Figure S1M) , whereas its protein stability was significantly reduced (Figures 1F and 1G) . This effect was efficiently blocked by the proteasome inhibitor MG-132 ( Figure 1C ), and restoration of SS18-SSX levels correlated positively with increased conjugation of poly-ubiquitin chains ( Figure 1H ). Our findings indicate the existence of as-yet-undefined ubiquitin ligases that target SS18-SSX for proteasomal degradation.
MULE Ubiquitin Ligase Binds to SS18-SSX and Promotes Its Degradation
Next, we performed anti-FLAG immunoprecipitation to purify SS18-SSX-interacting proteins. Mass spectrometric analysis of the peptides uniquely enriched after HDAC inhibitor stimulation led to identification of MCL-1 ubiquitin ligase E3 (MULE), a HECT-type enzyme that plays a central role in the regulation of cell proliferation and tumorigenesis (Shmueli and Oren, 2005; Kao et al., 2018) (Figures 2A and 2B ). Its interaction with the fusion oncoprotein was readily detected in both proximity ligation and immunoprecipitation assays ( Figures 2C-2E ). This binding event seemed to involve two fundamental domains in MULE, WWE and UBM, which co-occupied the repression domain (SSXRD) at the C-terminal end of SS18-SSX ( Figures  3A-3D ). Interestingly, there exists an alternatively spliced product of the SSX2 gene (dos Santos et al., 2000) , containing a different C-terminal region ( Figure S2A ). We found that this variant failed to interact with MULE in SYO-1 cells, regardless of HDAC inhibitor stimulation . Given the fact that MULE neither binds wild-type SS18 nor does its deletion affect SS18 protein expression ( Figures  S2E and S2F ), we reasoned that the C-terminal SSXRD may play an indispensable role for SS18-SSX recognition by MULE E3 ligase.
We continued to assess whether SS18-SSX is a substrate of MULE, and found that in vitro synthesized fusion oncoprotein could be poly-ubiquitinated by cell extracts prepared from wild-type but not Mule-knockout mouse embryonic fibroblasts ( Figures 4A-4C ). Consistently, depletion of MULE by short hairpin RNA in SYO-1 cells prevented endogenous SS18-SSX ubiquitination upon HDAC inhibitor stimulation ( Figure 4D ). Removal of MULE-binding SSXRD domain strikingly reduced SS18-SSX ubiquitination levels ( Figure 3E ), suggesting that MULE ubiquitinates the fusion oncoprotein largely through their physical interaction. It should be noted that the SYT N-terminal Homolog (SNH) motif of SS18-SSX also contributed to MULEmediated ubiquitination ( Figure 3E ). Given that the SNH-deleted (DSNH) mutant retained binding to MULE ( Figure 3D ), we reasoned that the critical SS18-SSX ubiquitination sites may be located within the SNH region. Indeed, previous studies have identified a lysine residue (K13) within wild-type SS18 protein that is ubiquitinated in human cell lines (Mertins et al., 2013; Udeshi et al., 2013) . However, among four lysines, only mutating K23 to arginine (K23R) effectively blocked SS18-SSX ubiquitination ( Figure 3E ). Thus the mechanism underlying SS18-SSX ubiquitination likely differs from that for wild-type SS18. Together, these results provide molecular insights into MULE E3 ligase activity toward the fusion oncoprotein ( Figure 3F ).
To elucidate the biological significance of these findings, we examined the effect of the presence or absence of MULE on SS18-SSX protein expression upon HDAC inhibitor treatment. In SYO-1 cells, SS18-SSX levels fell after addition of FK228 and SB939. However, under the same conditions, the fusion oncoprotein avoided downregulation by MULE depletion ( Figure 4E ). More importantly, removal of MULE reduced the sensitivity of SYO-1 cells to HDAC inhibitors (Figures 4F and 4G) . This resistance was neither due to the reported role of MULE in degrading histones (Liu et al., 2005) nor due to epigenetic changes in global histone acetylation upon HDAC inhibitor treatment ( Figures S3A-S3C ). This might result at least partly from impaired turnover of SS18-SSX, which retained the ability to promote cell proliferation and transformation via HDAC-independent mechanisms. In addition, among several known substrates of Figure 1 . HDAC Inhibition Downregulates SS18-SSX Fusion Oncoprotein (A) Representative immunofluorescence analysis of human SS18-SSX2 expression in tumor sections prepared from SSM2 mice treated with vehicle (À) or FK228 (3 mg/kg). Human SSX2 antibody was used to detect the fusion oncoprotein; DAPI was used for nuclear staining. Scale bar, 25 mm. (B) Western blot analysis of human SS18-SSX2 expression in vehicle or FK228-treated SSM2 mouse tumors. Actin was used as a loading control. (C) Western blot analysis of the lysate from CRISPR/Cas9-modified SYO-1 cells treated with vehicle (À) or HDAC inhibitors (FK228, SB939, and PCI-24781), in the presence and absence of MG-132. FLAG/tubulin ratios were normalized to vehicle and are shown in the top panel. (D) Cell viability assay showing the sensitivity of Yamato-SS cells to FK228 and SB939 at different concentrations. Results represent mean G SD of three independent experiments. (E) Western blot analysis of SS18-SSX1 protein levels in DMSO-, FK228-, (100 nM), and SB939-(1 mM) treated Yamato-SS cell lysate. Tubulin was used as a loading control. (F) Western blot analysis of SS18-SSX (anti-FLAG) protein abundance in CRISPR/Cas9-modified SYO-1 cells upon 12-h treatment of DMSO or FK228, followed by exposure to cycloheximide (CHX, 100 mg/mL) for the indicated time. Actin serves as a loading control, and HDAC1 serves as a negative control, which stays constant regardless of FK228 treatment. (G) FLAG/actin ratios were normalized to the 0-h time point. Data represent mean G SD of three independent experiments. (H) Ubiquitination analysis of anti-FLAG immunoprecipitates from CRISPR-modified SYO-1 cells treated with DMSO, FK228, or SB939, in the presence of MG-132. Cell lysate (input) was applied to western blot analysis showing equal amounts of ubiquitin protein under all conditions, and mouse IgG was used as a negative control. MULE, we found that HDAC inhibitor treatment downregulated CTCF and b-catenin protein expression, and this reduction was closely dependent on MULE (Figures S3D and S3E) . CTCF is a multifunctional transcription factor that organizes chromatin architecture and controls genomic stability in various biological processes involved in tumorigenesis (Qi et al., 2012; Ghirlando and Felsenfeld, 2016; Song and Kim, 2017) . b-Catenin acts as a central regulator of the WNT signaling pathway, which has been extensively studied in many human cancer types and directly linked to the progression of synovial sarcoma (Barham et al., 2013; Trautmann et al., 2014; Barrott et al., 2015 Barrott et al., , 2018 Cironi et al., 2016; Sanchez-Vega et al., 2018) . Collectively, our findings point to MULE-mediated ubiquitination signaling as a potential fundamental target for HDAC inhibitors in tumor suppression.
HDAC Inhibition Stabilizes MULE by Acetylation and Dissociation of MDM2
We noted that MULE protein levels rose upon HDAC inhibitor treatment, without mRNA level changes (Figures S4A and S4B) . Similar effects were also observed after proteasome inhibition ( Figures 5A and S4C ), indicating the unstable status of MULE protein in synovial sarcoma cells. Consistent with this notion, recent studies have reported MULE degradation by the oncogenic E3 ligase MDM2 in human cancers (Kurokawa et al., 2013; Canfield et al., 2016) . We confirmed the endogenous interaction between MDM2 and MULE in both SYO-1 and Yamato-SS cells ( Figures 5B and S4D ). Knockdown of MDM2 by siRNAs led to increased levels of MULE, which inversely correlated with SS18-SSX downregulation and impaired cell viability (Figures 5C, 5D, S4E, and S4F) . This effect seems independent of the p53 tumor suppressor, a key target of MDM2, because SYO-1 cells express wild-type p53, but Yamato-SS cells harbor a mutant p53 (R273C) (Vlenterie et al., 2016). Consistent with this view, depletion of endogenous p53 failed to rescue SYO-1 cells from MDM2 knockdown ( Figures S4G-S4I ). These results indicate a predominant role for MDM2 control of MULE (but not p53) signaling in synovial sarcoma cells. Notably, this action could be reversed by the addition of FK228 and SB939, which suppressed MDM2 binding to MULE ( Figure 5E ). As a result, HDAC inhibition led to a decrease in MULE ubiquitination and an increase in its protein stability (Figures 5F, 5G, S4J, and S4K). In addition, we found that the response of SYO-1 cells to FK228 and SB939 treatment, similar to MDM2 knockdown, remained unaffected after p53 deletion ( Figures S4L-S4N ), further supporting the notion that HDAC-inhibitor-induced anticancer action relies largely on MDM2 regulation of MULE, rather than p53, in synovial sarcoma.
Given that HDAC inhibition affects biological functions mostly through protein acetylation (Verdin and Ott, 2015) , we investigated whether the same mechanism controls the MDM2-MULE interaction.
Recently, it has been discovered that acetylation of the lysine-rich domain (KRD) can remove its positive charge and interrupt its association with the negatively charged acidic domain (Wang et al., 2016 (Wang et al., , 2017 . Indeed, there does exist a lysine-rich stretch (amino acids 460-476) in the MDM2 protein, whereas MULE has an acidic domain between the residues 2425 and 2469. In support of these clues, we found structural evidence of MULE's acidic domain bound to the MDM2 KRD ( Figures 6A, S5A , and S5B). This interaction likely involved five evolutionarily conserved lysine residues within KRD ( Figures  S5C-S5F ), which were acetylated in endogenous and ectopically expressed MDM2 upon HDAC inhibitor treatment ( Figures 6B, 6C , S5G, and S5H). According to these properties, we generated a mutant MDM2 (5KR) in which all KRD lysine sites were replaced by arginine ( Figure 6D ). This acetylation-deficient mutation retained the ability of MDM2 binding to MULE, but exhibited resistance to HDAC-inhibitor-stimulated dissociation ( Figure 6E ). Point mutation analysis identified two acetylated lysines, K469 and K470, responsible for the release of MDM2 from MULE ( Figures 6F, 6G , S5I, and S5J). In line with this observation, K469 and K470 appeared to be the most effective sites of MDM2 acetylation after FK228 addition ( Figure S5H ). To further test this idea, we generated another MDM2 mutation in which the K469 and K470 residues were substituted to glutamine. This acetylationmimicked mutation resulted in a dramatic loss of the MDM2-MULE interaction even without HDAC inhibitor treatment ( Figures 6H and 6I ). Intriguingly, Moshe Oren and colleagues reported that acetylation of the neighboring lysines K466 and K467 impairs MDM2's E3 ligase activity (Wang et al., 2004) . However, a similar defect was not found when mimicking the acetylation of K469 and K470 ( Figure S5K ). Therefore different acetylation modifications in the KRD region might have distinct and cooperative roles in limiting MDM2 function.
HDAC2 Regulates the MDM2-MULE Interaction and Maintains SS18-SSX Protein Stability
Finally, it is important to determine which of the 11 HDAC family members act upstream of MDM2 ( Figure S6A ). We focused on two highly homologous members, HDAC1 and HDAC2, because they are most abundantly expressed in synovial sarcoma cells ( Figure 7A ) (Pacheco and Nielsen, 2012) , and because the compound FK228 mainly inhibits HDAC1/2 activity. Interestingly, MDM2 associated with both HDAC1 and HDAC2 ( Figure S6B ), and depletion of neither HDAC1 nor HDAC2, affected MDM2 protein abundance ( Figures S6C and S6D ). However, MDM2-MULE interaction was diminished in HDAC2-deficient cells ( Figures 7B and S6E) . Moreover, the amount of SS18-SSX protein (but not mRNA) was drastically reduced upon HDAC2 knockdown (Figures 7C, S6F, and S6H), similar to the results obtained in MDM2-knockdown cells. We did not observe any significant effects after depletion of either HDAC1 or its Class I homolog HDAC3 ( Figures S6G-S6I ). Therefore unlike HDAC1, which contributes to SS18-SSX-mediated gene regulation (Su et al., 2012; Cironi et al., 2016) , HDAC2 performs a nonredundant role in safeguarding the fusion oncoprotein from ubiquitin-mediated degradation.
DISCUSSION
The experiments presented here demonstrate a new mechanism for MDM2 inactivation, which is achieved through site-specific acetylation ( Figure 7D ). Repression of this acetylation is crucial to MDM2 interaction with its substrate MULE. In synovial sarcoma, the HDAC2 enzyme governs MDM2 substrate-binding activity; suppression of HDAC2 by RNA interference or small-molecule inhibitors allows dissociation and accumulation of the ubiquitin ligase MULE, leading to subsequent degradation of the SS18-SSX fusion oncoprotein, b-catenin, and CTCF. We provide mechanistic and functional evidence pointing toward the therapeutic implication for using HDAC inhibitors in synovial sarcoma treatment. Notably, this may not be limited to synovial sarcoma. For example, MDM2-mediated MULE downregulation has been reported to confer breast cancer resistance to the human epidermal growth factor receptor 2 inhibitor lapatinib (Kurokawa et al., 2013) . It is tempting to speculate that use of HDAC inhibitors in combination therapy may resensitize some currently incurable cancers to conventional treatment.
Parallel with our current work, we recognize that MDM2 can also interact with MULE in an HDAC2-independent manner. This binding event requires the hydrophobic p53-binding pocket of MDM2, which in turn provides a targeting site for the small-molecule antagonist Nutlin-3a to prevent MULE accommodation and degradation (Kurokawa et al., 2013) . In synovial sarcoma cells, however, Nutlin-3a treatment does not disrupt the MDM2-MULE complex, nor does it influence MULE protein expression (Figures S6J and S6K) . These different results indicate that instead of a two-site binding model, there exist at least two levels of MDM2 control of MULE-one acting in the forward direction involving the intermolecular contact, whereas the second acting in the reverse direction involving lysine acetylation to unlock the binding interface. It will be important to further examine if any of the other post-translational modifications have a similar role as MDM2 in the regulation of MULE stability and activity. These efforts may also lead the way to a better understanding of how MDM2 integrates diverse input signals to execute its ubiquitination function with a high degree of specificity.
Limitations of the Study
We do not know if HDAC2 regulates MDM2 acetylation in any cancer forms other than synovial sarcoma. With our experiments, it is also not known if HDAC2 has a similar role in noncancerous context. Under different physiological conditions, HDAC2 and other related HDAC members may distinctly target the same lysine residues for control of MDM2 acetylation and function. Another limitation of our current study is the inability to answer whether HDAC inhibitors also control the substrate targeting of MULE E3 ligase through lysine acetylation. At this moment, the importance of post-translational modifications in the differential regulation of MULE downstream targets remains an open issue for further investigation.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file. 
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Transparent Methods
Cell culture and chemicals
Human synovial sarcoma cell lines SYO-1 (Akira Kawai, National Cancer Center, Tokyo, Japan) and Yamato-SS (Kazuyuki Itoh, Osaka Medical Center for Cancer and Cardiovascular Diseases, Japan) were cultured in RPMI-1640 and DMEM (Invitrogen) respectively, supplemented with 10% fetal bovine serum (FBS) (Invitrogen). Human embryonic kidney 293 (HEK293) cells were purchased from American Type Culture Collection (ATCC) and maintained in DMEM with 10% FBS. All cell lines were grown at 37°C, 95% humidity and 5% CO2.
All chemicals used in this study are commercially available: FK228 (Selleck Chemicals), SB939 (Abcam), PCI-24781 (Santa Cruz Biotechnology), Geneticin/G418 (Invitrogen), MG-132 (Santa Cruz Biotechnology), Cycloheximide (BioVision) and DMSO (Sigma-Aldrich).
To achieve stable knockdown of human MULE and p53 genes, SYO-1 cells were infected with control or MULE/p53-specific shRNA lentiviruses in regular growth medium, supplemented with 5 µg/ml Polybrene (Santa Cruz Biotechnology). Selection was carried out using Puromycin (Santa Cruz Biotechnology) (at the final concentration of 10µg/ml) to remove non-transduced cells.
Resistant cells were then expanded and maintained in Puromycin-containing growth medium. The efficiency of knockdown was confirmed at the mRNA or protein levels. Control, MULE and p53 shRNA lentiviral particles were purchased from Santa Cruz Biotechnology.
To construct the 3×Flag tagging donor plasmid, we designed the dsDNA genomic blocks (IDT) corresponding to homolog arms of individual SSX2 isoform and sub-cloned them into the pFETCh plasmid. Cas9/gRNA oligos (IDT) were designed nearby the 3' stop codons of SSX2 and integrated into the PX330 plasmid. 2´10 6 cells were transfected with the two constructs (5µg each), using the Nucleofector Kit V (Lonza). After overnight incubation in regular medium, cells were subjected to G418 selection at the concentration of 400 µg/ml for 7-10 days. Resistant cells were expanded in regular medium for downstream applications. The sequences of gRNAs and genomic blocks are listed below: gRNAs and genomic blocks for SSX2A TGCATGCCTGTATCAAAGCATCTCATGTACCCCATAAGAATATACACC  TGCTGCGTACCCACAAAATAAAGAACAAAAATTATTTTAAAACACTAA  AAAACAATAAAATCAATTGCAGTAATAATATCAAAGCTCACCGATCACA  GATCACTATAGCAGATATAATAATAATGGAAAAGTGTAAAATTGGTGAG  AATTAAAAAAAAAAATTGCAGCATCTGCGAAGCAGTATGAACATGAGG  TGCAACAAAACAAGGTACGCCTGTGTGGCCTTAACAAATACGTGCTG  GATGAAAGGAGGTATGGGGGAATGTTCCCGTAAGTGAAGAGGTTGG  GAATCTAAGCCTGAGAAGGGAAGGAGCCAGAAGCTAAAACTTTAATT  GGCATTTGGCCTATGTTGGTGTGGATCTAAGGTCTCAGCCTCTCTAA  GCCAGAGAATGTGAAAAACTGGATGAAGAAGGCCCATGGGCACTTG  GGAGGAAGCAGGCATCTCCTTTTTTTGAGTAAACAGAGCCTAACACT  CTCCAACCTACCCAACCCTCACTTTCCAACTATTCTCCATCACAGGA  CCCAAAAGGGGGGAACATGCCTGGACCCACAGACTGCGTGAGAGA  AAAtAGtTGGgggagcggaggaggttccgg   HOM2: agttcttctgattcgaacatcTTTATGAAGAGATCAGCGACCCTGAGGAAGATG  ACGAGTAACTCCGTAAGAGAACCTTCCACTCATCCCCCACATCCCTG  CAGACGTGCTATTCTGTTATGATACTGGTATCCCATCTGTCACTTGCT  CCCCAAATCATTCCCTTCTTACAATTTTCTACTGTACAGCATTGAGGC  TGAACGATGAGAGATTTCCCATGCTCTTTCTACTCCCTGCCCTGTATA  TATCCGGGGATCCTCCCTACCCAGGATGCTGTGGGGTCCCAAACCC  CAAGTAAGCCCTGATATGCGGGCCACACCTTTCTCTAGCCTAGGAAT  TGATAACCCAGGCGAGGAAGTCACTGTGGCATGAACAGATGGTTCA  CTTCGAGGAACCGTGGAAGGCGTGTGCAGGTCCTGAGATAGGGCA  GAATCGGAGTGTGCAGGGTCTGCAGGTCAGGAGGAGTTGAGATTGC  GTTGCCACGTGGTGGGAACTCACTGCCACTTATTTCCTTCTCTCTTC  TTGCCTCAGCCTCAGGGATACGACACATGCCCATGATGAGAAGCAGA  ACGTGGTGACCTTTCACGAACATGGGCATGGCTGCGGACCCCTCGT  CATCAGGTGCATAGCAAGTGAAAGCAAGTGTTCACAACAGTGAAAAG TTGAGCGTCATTTTTCTTAGTGTGCCAAGAGTTCGATGTTAGCGTTTA CGTTGTATTTTCTTACACTcttggaaagtcctctccactg gRNAs and genomic blocks for SSX2B
Mouse work
All mouse experiments were approved by University of Utah and the University Health Network
Committees on Animal Care. To generate mouse synovial sarcomas, the conditional SSM2 mice TATTACCCATTGCATGCCTGTATCAAAGCATCTCATGTACCCCATAAGA  ATATACACCTGCTGCGTACCCACAAAATAAAGAACAAAAATTATTTTAA  AACACTAAAAAACAATAAAATCAATTGCAGTAATAATATCAAAGCTCAC  CGATCACAGATCACTATAGCAGATATAATAATAATGGAAAAGTGTAAAA  TTGGTGAGAATTAAAAAAAAAAATTGCAGCATCTGCGAAGCAGTATGA  ACATGAGGTGCAACAAAACAAGGTACGCCTGTGTGGCCTTAACAAAT  ACGTGCTGGATGAAAGGAGGTATGGGGGAATGTTCCCGTAAGTGAA  GAGGTTGGGAATCTAAGCCTGAGAAGGGAAGGAGCCAGAAGCTAAA  ACTTTAATTGGCATTTGGCCTATGTTGGTGTGGATCTAAGGTCTCAGC  CTCTCTAAGCCAGAGAATGTGAAAAACTGGATGAAGAAGGCCCATGG  GCACTTGGGAGGAAGCAGGCATCTCCTTTTTTTGAGTAAACAGAGCC  TAACACTCTCCAACCTACCCAACCCTCACTTTCCAACTATTCTCCATC  ACAGGACCCAAAAGGGGGGAACATGCCTGGACCCACAGACTGCGT  GAGAGAAAACAGCTGGTGATTTATGAAGAGATCAGCGACCCTGAGG  AAGATGACGAGgggagcggaggaggttccgg   agttcttctgattcgaacatcACTCATCCCCCACATCCCTGCAGACGTGCTATTC  TGTTATGATACTGGTATCCCATCTGTCACTTGCTCCCCAAATCATTCC  CTTCTTACAATTTTCTACTGTACAGCATTGAGGCTGAACGATGAGAGA  TTTCCCATGCTCTTTCTACTCCCTGCCCTGTATATATCCGGGGATCCT  CCCTACCCAGGATGCTGTGGGGTCCCAAACCCCAAGTAAGCCCTGA  TATGCGGGCCACACCTTTCTCTAGCCTAGGAATTGATAACCCAGGCG  AGGAAGTCACTGTGGCATGAACAGATGGTTCACTTCGAGGAACCGT  GGAAGGCGTGTGCAGGTCCTGAGATAGGGCAGAATCGGAGTGTGC  AGGGTCTGCAGGTCAGGAGGAGTTGAGATTGCGTTGCCACGTGGT  GGGAACTCACTGCCACTTATTTCCTTCTCTCTTCTTGCCTCAGCCTCA  GGGATACGACACATGCCCATGATGAGAAGCAGAACGTGGTGACCTT  TCACGAACATGGGCATGGCTGCGGACCCCTCGTCATCAGGTGCATA  GCAAGTGAAAGCAAGTGTTCACAACAGTGAAAAGTTGAGCGTCATTT  TTCTTAGTGTGCCAAGAGTTCGATGTTAGCGTTTACGTTGTATTTTCT  TACACTGTGTCATTCTGTTAGATACTAACATTTTCATTGATGAGCAAGA  CATACTTAATGCATATTcttggaaagtcctctccactg were bred to Myf5-Cre mice, so as to express SS18-SSX2 in myoblasts and mesenchymal precursor cells (Haldar et al. 2007 ). The resulting Myf5-Cre/SSM2 progenies at age 14 weeks were subjected to weekly administration of FK228 or vehicle, and sacrificed at age 17 weeks for tumor collection. Tumor tissues were fixed in formalin and paraffin-embedded as standard pathology blocks. Blocks were serially sectioned at 6-µm thickness onto Fisher Plus microscope slides, prior to Hematoxylin and Eosin (H&E) staining. For immunofluorescence assay, slides were deparaffinized and rehydrated, prior to heat-induced antigen retrieval in Tris-EDTA buffer (pH=9).
Non-specific staining was blocked by 10% goat serum in PBS for 60 min at room temperature, followed by incubation with human SSX2 antibody (BioSS Antibodies; 1:100 dilution in PBS with 10% goat serum) overnight at 4°C. After three PBS wash steps of 10 min, slides were incubated with the secondary goat anti-rabbit Alexa 594 antibody (Invitrogen) at 1:500 dilution for 30 min.
After three PBS wash, slides were counterstained with DAPI (1:500 dilution) for 5 min, and mounted with Cytoseal-60 (Thermo Scientific). Microscopy analysis was taken with an Olympus BX-63 microscope and an Olympus XM-10 camera. 
Mule
Proximity ligation assay (PLA)
Cells were incubated on 8-well chamber slides (Sigma-Aldrich) overnight to 80% confluent. After 16-hr treatment with HDAC inhibitors, in the presence of MG-132 (1µM), cells were washed with PBS, and fixed in 4% paraformaldehyde (PFA) (Santa Cruz Biotechnology) for 10 min at room temperature. Permeabilization was conducted with 0.5% Triton X-100 (in PBS) for 10 mins at room temperature. We used the Duolink kit (Sigma-Aldrich) for PLA experiments. Briefly, cells were blocked in Duolink Blocking Solution for 30 min at 37 °C, and incubated with primary antibodies (mouse anti-Flag, 0.5 µg/ml; rabbit anti-MULE, 1.0 µg/ml) for 90 min at room temperature, followed by 60-min incubation of the PLUS and MINUS probes at 37 °C. The probes were hybridized in the Duolink Ligation buffer for 30 min at 37°C, and PLA signals were strengthened by the amplification reaction (100 min at 37°C). Negative controls were set up with no primary antibodies. Slides were mounted using Duolink in situ mounting medium with DAPI and subjected to microscopy analysis.
Immunoprecipitation and western blots
Cell extracts were prepared using the RIPA Lysis Buffer system (Santa Cruz Biotechnology), and Protein structure modeling Models for MULE (amino acids 2261-2970) were generated using I-TASSER hybrid modeler, and for MDM2 (amino acids 418-491) using YASARA homology modeling. Docking analysis was performed using the HADDOCK server, followed by energy minimization of each predicted interaction using both the AMBER03 and YASARA2 force fields. Evolutionary analysis and codon selection work was done using our published Sequence-to-Structure-to-Function methods (Prokop et al. 2017) .
Ubiquitination analysis
For in vitro ubiquitination analysis, Myc-tagged SS18-SSX2 fusion protein was made by the TnT Quick Coupled Transcription/Translation system (Promega) and mixed with 35µg of either wildtype (WT) or Mule-null MEF cell extracts in the reaction buffer (50mM Tris-HCl, 10mM NaCl, 5mM MgCl 2 , 1mM DTT, 20µM MG-132, 5mM ATP). After 60-min incubation at 30°C, samples were subjected to anti-Myc immunoprecipitation using antibody-coated magnetic beads (crosslinking with 20mM dimethyl pimelimidate/DMP, Sigma-Aldrich). Proteins in the eluent were separated on 8% SDS-PAGE, followed by western blotting against Myc and ubiquitin. For in vivo ubiquitination study, cells were treated with HDAC inhibitors for 12 hr, followed by adding 20µM MG-132 for 6 hr. The lysate was prepared using RIPA Lysis Buffer (Santa Cruz Biotechnology), sonicated by the Bioruptor (10 sec ´ 3 cycles, low power) and subjected to immunoprecipitation (primary antibody: 4µg/assay). Beads were washed twice with the RIPA buffer, followed by three PBS/T washes, and boiled in Bio-Rad sample buffer for SDS-PAGE and western blot analysis.
Mass spectrometry
The protein samples were separated by 12.5% SDS-PAGE and subjected to in-gel digestion using trypsin (Kondo and Hirohashi 2006) . The tryptic digests were then subjected to liquid chromatography coupled with nanoelectrospray tandem mass spectrometry (Finnigan LTQ Orbitrap XL mass spectrometer; Thermo Fisher). The Mascot software package (version 2.5.1;
Matrix Science) was used to search for the mass of each peptide ion peak against the SWISS-PROT database (Homo sapiens, 20205 sequences in the Swiss prot_2015_09.fasta file) using the following parameters -3 or 4 missed cleavage; variable modifications: oxidation (Met) and acetylation (Lys); peptide tolerance: 10 p.p.m.; MS/MS tolerance: 0.8 Da; peptide charge: 2 + , 3 + and 4 + .
Cell viability and colony formation assays
Human synovial sarcoma cells were cultured at 60% confluence, and transfected with indicated siRNAs using Lipofectamine RNAiMAX (Invitrogen). After 72 hours, cell cultures were incubated with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution (Sigma-Aldrich), and MTT formazan was solubilized in acidic isopropanol with 0.04N HCl.
Absorbance was read at 570 and 630 nm with a colorimeter. Cell viability was calculated as the relative absorbance (570/630 nm), and normalized to control cells. To study drug effects, cell viability was examined at the 48-hr time point after treatment with HDAC inhibitors. For colony formation assay, control and MULE-deficient SYO-1 cells were grown to 80% confluence, and treated with HDAC inhibitors for 24 hours. Cells were seeded into 6-well plates at the density of 600 cells/well in regular growth medium, and cultured for 10 days with medium change every 2-3 days. Finally, cells were fixed with 10% formaldehyde for 30 min at room temperature and stained with 0.5% crystal violet solution (20% methanol) for 10 min at room temperature. Plates were washed with water and air-dried overnight, prior to scanning.
RNA interference (RNAi)
Two individual small interfering RNAs (siRNAs) were purchased from Thermo Stealth RNAi collection, for MDM2 (HSS142909, HSS142911), HDAC1 (HSS104725, HSS104726), HDAC2 (HSS104728, HSS104729) and HDAC3 (HSS113050, HSS113051). At 60% confluence, cells were transfected with indicated siRNAs at the final concentration of 20 nM, using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's instructions. For human SS18 (Santa Cruz Biotechnology) and SS18-SSX2 (sense: CAAGAAGCCAGCAGAGGAATT, antisense:
UUCCUCUGCUGGCUUCUUGTT), RNAi reactions were carried out with 40-80 nM siRNAs.
Knockdown efficiency was confirmed by western blots.
Plasmid DNA construction and transfection
Flag-and HA-tagged human MULE constructs have been used in previous studies (Zhang et al. 2011; Yi et al. 2015) . SS18-SSX2 cDNA and deletion mutants (ΔSNH, ΔQPGY and ΔRD) were synthesized via Integrated DNA Technologies (IDT) and inserted into a Gateway pENTR1A vector. To make Myc-tagged SS18-SSX2, EcoR1-Not1 fragment was sub-cloned into the pcDNA4 mammalian expression vector (Invitrogen). To generate GFP-tagged fusions, pENTR1A constructs were subjected to Gateway recombination reactions, creating pcDNA-DEST47 (Invitrogen) expression clones. For lysine-to-arginine (KR) and -glutamine (KQ) substitution experiments, we used the Q5 Site-Directed Mutagenesis kit (New England Biolabs) with the PCR primers listed below. For overexpression, cells were transiently transfected with indicated plasmid DNA using Lipofectamine 3000 reagent (Invitrogen). After 48 hours post transfection, cells were harvested for downstream applications.
The sequences of PCR primers used for site-directed mutagenesis
Real-time qPCR and RNA-sequencing
Total RNA was isolated and then transcribed to cDNA using the Qiagen RNeasy kit and the high- MULE-specific primer/probe sets (Applied Biosystems). SS18-SSX2 fusion oncogene expression (5'-TGACCAGATCATGCCCAAG-3'; 5'-GGGTCCAGATCTCTCGTGAA-3') was measured by SYBR Green qPCR assay (Applied Biosystems). All transcript levels were normalized to expression of 18S ribosomal RNA (rRNA). For sequencing analysis, RNA isolated with RNAzol (Sigma-Aldrich) was quality-checked for the integrity scores greater than 8 on the Aligent Bioanalyzer, and then prepared and indexed with Truseq Stranded mRNA kit (Illumina).
Sequencing was done on an Illumina HiSeq 2500 50 Paired End run. All data were aligned to hg19 using TopHat2, and differential expression was demonstrated through Cufflinks and normalized FPKM numbers.
Histone extraction
Cells were suspended at the density of 4´10 7 cells per ml in the solution (10mM HEPES, 10mM
KCl, 1.5mM MgCl 2 , 0.34M sucrose, 10% glycerol, 1mM DTT, 0.2% Triton X-100) and incubated for 5 min on ice. Nuclei were collected in pellet by low-speed centrifugation (4 min, 1,300´g, 4°C), washed once with PBS/T (0.5% Triton X-100) and resuspended in 0.2N HCl. After overnight incubation at 4°C, the supernatant was collected by high-speed centrifugation (10 min, 6,500´g, 4°C) and neutralized with 1M Tris-HCl (pH=8). Histone samples were separated on 15% SDS-PAGE and analyzed by coomassie blue staining (Protea SuperBlue) and western blotting. 
